IAG’s Team is Presenting at ACR / ARHP Annual Meeting, Chicago, 19-24 October 2018
It is now widely accepted that inflammation is the major factor driving the progression of structural damage in auto-immune diseases such as rheumatoid, psoriatic arthritis as well as degenerative diseases conditions such as osteoarthritis. Development of novel therapies in other auto-immune diseases, including lupus, gout, scleroderma and lupus nephritis as well as break-through therapies which target pain (low back pain and OA pain for instance) is linked to the reduction of inflammation.
Several imaging biomarkers have been identified to understand pain through the use of imaging and to predict clinical outcomes as early as possible. At ACR, we will be presenting new data on using imaging and non-imaging biomarkers to differentiate patients with different rheumatic conditions, to bring machine learning technique to identify the right population with a risk of early disease onset as well as how to use MRI combined inflammation and combined damage scores to predict successful tapering with the treatment dose.
Imaging Biomarker Based Patient Stratification: Initial Data and Validation in Four Most Common Knee Arthritic Diseases
Poster: Sunday, October 21, 2018, 9:00-11:00, ACR Poster Session A: Imaging of Rheumatic Diseases Poster I: MRI.
Dose Tapering and Discontinuation of Biological Therapy in Rheumatoid Arthritis Patients in Routine Care – 2-Year Outcomes and Predictors
Oral: Tuesday, October 23, 2018, 14:30-16:00, Session Title: ACR Abstract: RA–Treatments IV: Strategy (2820–2825).
The Value of Adding MRI to a Clinical Treat-to-Target Strategy in Rheumatoid Arthritis Patients in Clinical Remission: Clinical and Radiographic Outcomes from the Imagine-RA Randomized Controlled Trial
Poster: Monday, October 22, 2018, 9:00-11:00, ACR Poster Session B: Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster II: Diagnosis and Prognosis.
An MRI Guided Treat-to-Target Strategy in Rheumatoid Arthritis Patients in Clinical Remission Improved MRI Inflammation but Not Damage Progression – Results from the Imagine-RA Randomized Controlled Trial
Oral: Sunday, October 21, 2018, 14:30 – 16:00, ACR Abstract: Imaging of Rheumatic Diseases I: MRI & CT (863–868).
ABSTRACT NUMBER: 2937
Anti-Vinculin Antibodies in Systemic Sclerosis (SSc): A Potential Biomarker Linking Vascular and Gastrointestinal System Involvement in Two Phenotypically Distinctive SSc Groups
Oral: Wednesday, October 24, 2018, 9:00-10:30, Session Title: Systemic Sclerosis & Rel D/O III:Cohort Study, Biomarkers, & Response(2934–2939).
ABSTRACT NUMBER: 1111
CBS004, a Novel Monoclonal Antibody Against Bdca-2 Inhibits TLR-Induced Activation of Human pDC in Vitro and In Vivo. a Novel Therapeutic Target for Systemic Sclerosis
Poster: Monday, October 22, 2018, 9:00-11:00, Session Title: Session B: Systemic Sclerosis and Related Disorders – Basic Science Poster II.
ABOUT
The American College of Rheumatology’s Annual Meeting (ACR / ARHP Annual Meeting) will be held in Chicago, Illinois, 19-24 October 2018, bringing leading rheumatology experts, drug development professionals and academics.
About Image Analysis Group (IAG)
IAG, Image Analysis Group is a unique partner to life sciences companies. IAG leverages expertise in medical imaging and the power of Dynamika™ – our proprietary cloud-based platform, to de-risk clinical development and deliver lifesaving therapies into the hands of patients much sooner. IAG provides early drug efficacy assessments, smart patient recruitment and predictive analysis of advanced treatment manifestations, thus lowering investment risk and accelerating study outcomes. IAG bio-partnering takes a broader view on asset development bringing R&D solutions, operational breadth, radiological expertise via risk-sharing financing and partnering models.
Learn more: www.ia-grp.com
Reach out: imaging.experts@ia-grp.com
Follow the Company: Linkedin